.jpg "Spark Therapeutics (NASDAQ: ONCE)")
In a report released today, Difei Yang from Mizuho Securities reiterated a Buy rating on Spark Therapeutics (NASDAQ: ONCE). The company’s shares closed yesterday at $76.32.
Yang commented:
“We are raising our PT from $79 to $91 per share to reflect the priority voucher sale as well as probability adjusted M&A premium. Given recently completed transactions in the gene therapy space and our view that Spark is one of the highest-quality gene therapy companies, we believe it is reasonable to apply a conservative M&A premium to our valuation. We reiterate our Buy rating on the stock.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 20.8% and a 50.7% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Alder Biopharmaceuticals, and Audentes Therapeutics.
Currently, the analyst consensus on Spark Therapeutics is Strong Buy and the average price target is $75.40, representing a -1.2% downside.
In a report issued on April 19, William Blair also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Based on Spark Therapeutics’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $7.41 million and GAAP net loss of $61.82 million. In comparison, last year the company earned revenue of $1.27 million and had a GAAP net loss of $52.29 million.
Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases. The company was founded by Jean Bennett, Beverly Davidson, Katherine A. High, Jeffrey D. Marrazzo, J.
